FindTrial
Sign In

Study to verify polypharmacy in patients with diabetes, hypertension, and their coexistence

Assessing polypharmacy burden in diabetes, hypertension, and their coexistence - NIL

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/12/099117
Enrollment
100
Registered
2025-12-15
Start date
Unknown
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E00-E89- Endocrine, nutritional and metabolic diseases

Interventions

Intervention1: Nil: Nil

Sponsors

Indus International Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients aged 18 years and above Diagnosed with type 2 diabetes mellitus or hypertension. Prescribed more than 1 medication.

Exclusion criteria

Exclusion criteria: Pregnant/lactating women. Patients on short-term therapy only (e.g., antibiotics for acute infection). Incomplete prescriptions

Design outcomes

Primary

MeasureTime frame
Mean number of drugs per prescription in diabetic and hypertensive patients.Timepoint: Baseline, Day 0, Day 7, and 6 months—

Secondary

MeasureTime frame
Proportion of patients with polypharmacy. Most commonly prescribed drug classes (antidiabetics, antihypertensives, statins, gastroprotective). Frequency & severity of drug drug interactions. Differences in prescribing between OPD & IPD patients Timepoint: Baseline Day 0 Day 7 & 6 months—

Countries

India

Contacts

Public ContactAvantika Chandra

Indus International Hospital

msiih@indushospitals.com8872735888

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 7, 2026